Premium
Anti‐(+)‐Methamphetamine Monoclonal Antibody Antagonists Designed to Prevent the Progression of Human Diseases of Addiction
Author(s) -
Gentry W B,
RüediBettschen D,
Owens S M
Publication year - 2010
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.2010.155
Subject(s) - methamphetamine , meth , addiction , clinical pharmacology , abstinence , monoclonal antibody , medicine , pharmacology , vulnerability (computing) , psychiatry , immunology , antibody , computer security , chemistry , monomer , organic chemistry , acrylate , computer science , polymer
Anti‐(+)‐methamphetamine monoclonal antibodies (mAbs) have the potential to reduce the devastating behavioral and societal effects of the worldwide epidemic of (+)‐methamphetamine (METH) addiction and transform the treatment paradigm for diseases of addiction. These novel, protein‐based medications could play a vital role in helping patients to achieve sustainable abstinence from METH abuse by serving as an in vivo , around‐the‐clock sentry against a patient's vulnerability to relapse. Clinical Pharmacology & Therapeutics (2010) 88 3, 390–393. doi: 10.1038/clpt.2010.155